Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Jan. 31, 2026	Jan. 31, 2025
Cash flows from operating activities:
Net income (loss)	$ (15,031,211)	$ 18,906,468
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on related party investment – QCLS	(2,089,000)	(21,395,734)
Issuance costs – Series C preferred stock and warrants	1,234,553	0
Loss on issuance of Series C preferred stock	215,000	0
Gain on re-fair value of warrants	(106,000)	0
Non-cash interest income	(300,000)	(300,000)
Stock issued for compensation - RSUs	892,500	0
Stock-based compensation - options	181,476	414,693
Unrealized loss on marketable equity securities	294,065	(72,632)
Change in fair value of warrant liabilities	8,335,135	(8,400,000)
Change in fair value of derivative liability	(859,000)	(2,184,000)
Change in fair value of convertible note receivable - Femasys	(1,304,000)	(601,000)
Change in fair value of warrant asset – Femasys	2,155,000	1,830,000
Change in fair value of investment – QCLS	3,485,000	1,642,050
Change in fair value of warrants - QCLS	(18,000)	8,123,684
Change in assets and liabilities:
Decrease in prepaid expenses and other current assets	65,095	52,438
Increase in accounts payable	714,459	95,578
Decrease in accrued expenses	(1,625,424)	(49,470)
Net cash and cash equivalents used in operating activities	(3,760,352)	(1,937,925)
Cash flows from investing activities:
Proceeds from investment - note receivable	5,000,000	0
Investment in preferred stock and warrants in QCLS	(3,000,000)	(7,000,000)
Net cash and cash equivalents provided by (used in) investing activities	2,000,000	(7,000,000)
Cash flows from financing activities:
Repurchase of common stock, net	(401,625)	(2,370,733)
Redemption of preferred stock	0	(22,486,875)
Net proceeds from issuance of Series C convertible preferred stock	6,268,866	0
Net proceeds from exercises of warrants	1,046,760	0
Payment of Series C convertible preferred stock dividends	(162,606)	0
Net cash and cash equivalents provided by (used in) financing activities	6,751,395	(24,857,608)
Effect of currency rate exchange on cash and cash equivalents	2,329	(975)
Net increase (decrease) in cash and cash equivalents	4,993,372	(33,796,508)
Cash and cash equivalents at beginning of the period	15,172,163	50,179,968
Cash and cash equivalents at end of the period	20,165,535	16,383,460
Supplemental disclosure of non-cash investing and financing activities:
Reclassification of Series B Convertible Preferred Stock and dividends to current liability	0	16,190,179
Accretion of discounts to redemption value of Series B Preferred Stock	0	3,193,404
Accrual of Series C Convertible Preferred Stock dividends	195,097	0
Accrual of Series C Convertible Preferred Stock issuance costs	86,419	0
Accretion of discounts to redemption value of Series C Preferred Stock	3,106,653	0
Initial fair value of investment in QCLS Series H preferred shares	3,483,000	0
Initial fair value of investment in QCLS Series H warrants	1,606,000	0
Non-cash derivative liability at initial fair value	1,995,000	0
Non-cash warrant liability at initial fair value	5,220,000	0
Non-cash redemption of Series C convertible preferred stock	2,234,330	0
Change in fair value associated warrant exercises	599,135	0
Fair value of contingently redeemable placement agent warrants	417,000	0
Excise tax accrued on repurchase of common stock	$ 0	$ 23,707